Skip to content
Optically-Pumped Magnetometer (OPM) Magnetoencephalography (MEG)
Future Tech

Curated by Surfaced Editorial·Healthcare·3 min read
Share:

OPM-MEG is a next-generation neuroimaging technique that measures the tiny magnetic fields produced by electrical currents in the brain, offering a direct and non-invasive way to observe neural activity. It utilizes optically pumped magnetometers, small sensors that detect magnetic fields by measuring changes in how light interacts with alkali metal vapors (like rubidium or cesium) due to the Zeeman effect. Major players in this field include the University of Nottingham, UCL (University College London), and companies like Cerca Magnetics Limited. This technology is currently in advanced research and prototype development, with early systems being deployed in specialized research centers. In December 2023, a study published in *Nature Photonics* showcased OPM-MEG's ability to map brain activity in children with epilepsy more accurately than traditional MEG. Compared to conventional MEG, which requires bulky, cryogenically cooled SQUIDs and a fixed helmet, OPM-MEG sensors are much smaller, operate at room temperature, and can be worn closer to the scalp, allowing for more natural head movements and better signal quality.

Why It Matters

OPM-MEG promises to transform our understanding of brain function and diagnosis of neurological disorders, impacting an estimated 50 million epilepsy patients and countless others with cognitive impairments globally. Imagine children with developmental disorders undergoing brain scans while freely moving, or neurosurgeons pre-operatively mapping critical brain areas with unprecedented precision, improving surgical outcomes. Academic researchers and specialized medical device companies are poised to benefit, potentially disrupting the market for traditional MEG and even fMRI for certain applications. Technical hurdles include minimizing environmental magnetic noise, improving sensor array density, and developing robust head-cast systems for clinical populations. Broader clinical adoption is likely within 7-12 years. The UK, Germany, and Japan are leading the charge in OPM-MEG development. A second-order consequence might be the creation of highly personalized brain models for each individual, leading to tailored cognitive training or therapeutic interventions.

Development Stage

Early Research
Advanced Research
Prototype
Early Commercialization
Growth Phase

Enjoyed this? Get five picks like this every morning.

Free daily newsletter — zero spam, unsubscribe anytime.